CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3 enrolled
Drug / intervention
FUSION closed loop glucose control systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05386849
NCT05386849N/ACompleted
CompareCT.gov

Demonstration of an Artificial Intelligence Based Closed Loop Glucose Control System as a Therapeutic Modality in Type 2 Diabetic Patients

Ideal Medical Technologies·interventional·Posted May 23, 2022·Updated Mar 27, 2026

In Brief

A clinical study evaluating FUSION closed loop glucose control system for Diabetes Mellitus, Type 2. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This is a proof of concept safety study of an artificial intelligence based closed loop glucose control system designed for use in the intensive care unit setting. The type 2 diabetic subjects in this study will have their glucose controlled to a range of 100-140 mg/dL by a novel artificial intelligence based closed loop glucose control system for a period of 24 hours. The subjects will consume three standardized meals during the 24 hour study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsEmory University

Timeline

N/ACompletedFinished
2023202420252026
First PostedMay 23, 2022
Enrollment StartMay 9, 2022
Primary CompletionJul 19, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.1 years ago

Interventions

FUSION closed loop glucose control systemdevice

The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.